Slide 1: Meet AZN management: ASCO 2019 Breakout 1: sales and marketing
Marquis_CONFERENCE AZ2019 Meet AZN management: ASCO 2019 Breakout 1: sales and marketing Dave Fredrickson, Executive Vice President, Oncology Business Unit Greg Rossi, Vice President, Lynparza franchise and Market Access 3 June 2019
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, pe
Slide 3: AstraZeneca's commercial strategy in Oncology
Focused Global franchises presence AstraZeneca’s US 81% sales Japan #2 oncology commercial strategy in growth company Oncology: May May providing the right treatment, for the right EU China patient, at the right time, 34% sales #2 oncology Lung cancer growth in the key franchises Lynparza/DDR1 compa
Slide 4: Lung cancer: Tagrisso – Worldwide 1st-line rollout underway following strong initial launches
Lung cancer: Tagrisso Worldwide 1st-line rollout underway following strong initial launches Underlying demand Asian patients are especially in focus due continues in the US to higher prevalence of the EGFR mutation • 1st-line EGFRm1 new- Western Asian patient starts currently at >60% patients patien
Slide 5: Lung cancer: Imfinzi – US market uptake strong; greater opportunity worldwide
Lung cancer: Imfinzi US market uptake strong; greater opportunity worldwide Initiatives to further increase More patient need ex-US; EU reimbursement ongoing benefits to patients in the US Initiate Extend Treat to only ~1/5 of but ~4/5 of potential early duration progression sales are ex-US patients
Slide 6: Lynparza: Continuing success in a competitive market
Lynparza Continuing success in a competitive market Cementing leadership SOLO-1 data boosting US Lynparza moving fast in ovarian cancer 2nd-line maintenance starts beyond ovarian cancer GY004/GY005 Combo w/cediranib ~80% PSR1 and PRR2 in ‘all comers’ US market share of BRCAm4 breast cancer PAOLA-1 C
Slide 7: Trastuzumab deruxtecan in breast cancer and beyond
Trastuzumab deruxtecan in breast cancer and beyond Opportunities across treatment settings in breast cancer Neo-adjuvant / adjuvant 1st-line metastatic 2nd-line metastatic 3rd-line metastatic Post neo-adjuvant Replace Replace HER2-positive trastuzumab chemotherapy + Replace Post emtansine breast can
Slide 8: Haematology: Calquence Phase III data readout in CLL provides momentum
Haematology Calquence Phase III data readout in CLL1 provides momentum Key data readouts and milestones $94m Trial/milestone Phase Status ACE-CL-309 ASCEND in Positive top-line III worldwide Calquence relapsed/refractory CLL results announced sales since launch ACE-CL-007 ELEVATE-TN in Data anticipa
Slide 9: Q&A
Q&A
Slide 10: Back-up slides from here - to be deleted
Back-up slides from here - to be deleted Source: Morgan Stanley investment research. 10
Slide 11: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab